Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-6: Ivermectin 600 µg/kg in COVID-19 Outpatients
NCT05894538Phase 3Completed
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivermectin in coronavirus disease 2019 (COVID-19). Started Feb 2022; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05894538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894538.